NIPAL2

Across TCGA pan-cancer cohorts, NIPAL2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NIPAL2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NIPAL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NIPAL2 expression acts as an unfavorable survival marker.

LUAD, HNSC, and LSCC are the cancer types where NIPAL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.388	1.000	.009	20	view →
HNSC	DFS	Median	All	0.417	1.000	.016	8	view →
LSCC	DFS	Median	All	0.424	0.988	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NIPAL2–LUAD (DFS)

Open the LUAD breakdown →